Dermatomycoses: Clinical Trials

55 trials for Dermatomycoses, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

55 completed. 55 Phase 2, 4 Phase 3, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 255Completed 55
Phase 34Completed 4
Phase 13Completed 3

Follow Dermatomycoses: new trials by email Literature Review of Dermatomycoses trials Research Report on Dermatomycoses

Trials (filtered) newest first · largest first

All 55 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pilot Study of Swift Microwave Device for Onychomycosis
Swift Microwave treatment - weekly x 4wks, Swift Microwave treatment - Every other week x 4wks, Swift Microwave treatment - Every other week x 24wks - Onychomycosis of Toenail
Phase 1 / Phase 2CompletedMediprobe Research Inc.392023-03-272024-11-18
A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail
BB2603-1, BB2603-3, BB2603-10 - Distal Subungual Onychomycosis, Fungal Infection
Phase 2CompletedBlueberry Therapeutics1112021-03-222023-08-01
A Trial to Evaluate the Safety and Antimicrobial Efficacy of DBI-002 Probiotic in Adults With Tinea Versicolor
DBI-002 probiotic gel, Aqueous gel - Tinea Versicolor
Phase 2CompletedDermBiont, Inc.342021-03-162025-07-03
A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis
UHE-103A1 cream, UHE-103A2 cream, UHE-103B cream - Tinea Pedis
Phase 2CompletedTherapeutics, Inc.2402019-03-152021-10-28
A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis
Janthinobacterium lividum - Tinea Pedis
Phase 2CompletedDermBiont, Inc.122019-02-192025-06-17
Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
SUBA itraconazole, Conventional itraconazole - Invasive Fungal Infections
Phase 2 / Phase 3CompletedUniversity of Alabama at Birmingham882018-09-172023-07-07
Clinical Assessment of Voriconazole Self Nano Emulsifying Drug Delivery System Intermediate Gel
voriconazole gel once daily, voriconazole gel twice daily, placebo - Tinea Versicolor
Phase 2CompletedSara Botros302018-02-152019-10-01
Clinical Assessment of Itraconazole Self Nano Emulsifying Drug Delivery System Intermediate Gel
itraconazole gel once daily, itraconazole gel twice daily, placebo - Tinea Versicolor
Phase 2CompletedSara Botros302018-02-152019-10-01
Proof-of-Concept Superiority Trial of Fosravuconazole Versus Itraconazole for Eumycetoma in Sudan
Fosravuconazole, Itraconazole - Mycetoma
Phase 2CompletedDrugs for Neglected Diseases1042017-05-092024-07-18
Three-Arm Trial of Novel Treatment for Tinea Pedis
Experimental Drug SESC 01, Placebo, Terbinafine Hydrochloride - Tinea Pedis
Phase 2CompletedSouth End Skin Care902017-01-032017-10-06
CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis
Amphotericin B - Candidiasis, Chronic Mucocutaneous
Phase 2CompletedMatinas BioPharma Nanotechnologies, Inc.42016-09-272024-08-07
Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot
Nitric Oxide, Water - Tinea Pedis
Phase 2CompletedNitric Solutions Inc.202016-08-132019-09-20
SB208 for the Treatment of Tinea Pedis
SB208 2%, SB208 4%, SB208 16% - Tinea Pedis
Phase 2CompletedNovan, Inc.2222016-07-192019-01-10
Efficacy, Safety, and Tolerability of HTS-519 Insert in Patients With Toenail Fungus of the Big Toenail
HTS-519 Insert - Onychomycosis
Phase 2CompletedHallux, Inc.302016-07-012021-11-02
Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study
NVXT topical, Placebo (Vehicle) Topical - Onychomycosis
Phase 2CompletedSun Pharmaceutical Industries, Inc.1842016-03-212018-12-20
Design and Clinical Evaluation of a School Meal With Deworming Properties
Ujiplus, Albendazole, uji - Helminthiasis, Tinea Capitis
Phase 2 / Phase 3CompletedKenya Medical Research Institute3262015-05-012016-09-07
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail
VT-1161, Placebo - Onychomycosis
Phase 2CompletedViamet2592015-02-172020-11-04
Evaluation of the Suitability of PD P 506 A in the PDT of Distal Subungual Onychomycosis (DSO) of the Great Toenail.
PD P 506 A - Onychomycosis
Phase 2Completedphotonamic GmbH & Co. KG252015-01-012017-09-19
Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail
NVXT Solution, Vehicle of test product - Onychomycosis
Phase 2CompletedSun Pharmaceutical Industries, Inc.472014-12-012018-09-19
Clinical Trial Comparing BL123 Versus Ketoconazole in Patients With Tinea Pedis
Dapaconazole, Ketoconazole - Tinea Pedis
Phase 2CompletedGilberto De Nucci602014-07-012016-07-07

Showing 20 of 55. Sign in to see all of them.

Narrower conditions

Onychomycosis (30)  ·  Tinea Pedis (13)  ·  Mycoses (6)  ·  Blastomycosis (3)  ·  Communicable Diseases (3)  ·  Histoplasmosis (3)  ·  Rare Diseases (3)  ·  Sporotrichosis (3)  ·  Tinea (3)  ·  Tinea Versicolor (3)  ·  Immune System Diseases (2)  ·  Tinea Cruris (2)  ·  Anemia (1)  ·  Candidiasis, Chronic Mucocutaneous (1)  ·  Coccidioidomycosis (1)

Broader conditions

Bacterial Infections and Mycoses (55)  ·  Skin Diseases, Infectious (55)  ·  Skin and Connective Tissue Diseases (55)  ·  Infections (54)  ·  Skin Diseases (54)  ·  Mycoses (49)  ·  Tinea (43)  ·  Nail Diseases (30)  ·  Pathological Conditions, Signs and Symptoms (17)  ·  Signs and Symptoms (13)  ·  Skin Manifestations (13)  ·  Foot Dermatoses (12)  ·  Foot Diseases (12)  ·  Pruritus (12)

Interventions

Terbinafine (5)  ·  tavaborole (5)  ·  Itraconazole (4)  ·  1-(2-(2,4-dichlorophenyl)-2-(4-(trifluoromethyl)benzyloxy)ethyl)-1H-imidazole (2)  ·  Fluconazole (2)  ·  Nitric Oxide (2)  ·  VT-1161 (2)  ·  Albendazole (1)  ·  Amphotericin B (1)  ·  BANG polymer gel (1)  ·  Econazole (1)  ·  Exercise (1)  ·  Ketoconazole (1)  ·  Miconazole (1)  ·  Nitrogen (1)

Sponsors

Pfizer (7)  ·  Nitric BioTherapeutics, Inc (4)  ·  DermBiont, Inc. (2)  ·  National Center for Research Resources (NCRR) (2)  ·  Sara Botros (2)  ·  Sun Pharmaceutical Industries, Inc. (2)  ·  Topica Pharmaceuticals (2)  ·  Viamet (2)  ·  Abeona Therapeutics, Inc (1)  ·  Almirall, S.A. (1)  ·  AmDerma (1)  ·  Bayer (1)  ·  Blueberry Therapeutics (1)  ·  Celtic Pharma Development Services (1)  ·  Dow Pharmaceutical Sciences (1)

Countries

United States (26)  ·  Canada (8)  ·  Germany (4)  ·  Mexico (4)  ·  Dominican Republic (2)  ·  Egypt (2)  ·  Brazil (1)  ·  Czechia (1)  ·  El Salvador (1)  ·  Iceland (1)  ·  India (1)  ·  Panama (1)  ·  Poland (1)  ·  Puerto Rico (1)  ·  Saint Kitts and Nevis (1)

Top investigators

William Dismukes (3)  ·  Sara R Botros, bachelor of clinical pharmacy (2)  ·  Aditya Gupta, MD,PhD (1)  ·  Ahmed Fahal, Prof (1)  ·  Alexandra Freeman, MD (1)  ·  Alicia Barba, MD (1)  ·  Alicia Bucko, DO (1)  ·  Andrej Spec, MD (1)  ·  Bernard Goffe, MD (1)  ·  Boni Elewski, MD (1)  ·  Brock McConnehey,, DO (1)  ·  Carl Schanbacher, MD (1)

Results publications

PMID 21967490, PMID 23377392, PMID 30526582, PMID 32421854, PMID 32457106, PMID 35699443, PMID 38440302, PMID 39098321, PMID 39624747, PMID 40433693

NIH funding

2008 (1), 2009 (1)